Does a GLP-1 improve cholesterol during perimenopause?

# Does a GLP-1 improve cholesterol during perimenopause?

If your cholesterol numbers drifted the wrong way in your forties or fifties and nothing about your diet had changed, you are not imagining it. Perimenopause quietly reshapes the lipid panel, and that is part of why the heart deserves more attention in these years, not less. This piece walks through what shifts in the menopause transition, what weight medicines actually do to lipids, and where the evidence is solid versus where it is a fair extrapolation rather than a menopause-specific result.

Key takeaways

Dr. Linda's take

Patients often bring me a lab result before they bring me a symptom. The LDL crept up, the total cholesterol crept up, and they want to know what they did wrong. Usually the honest answer is nothing. The lipid panel changes around the final menstrual period on its own, and it happens across ethnic groups, which tells me it is biology and not willpower.

So when someone asks whether one of these medicines will fix her cholesterol, I try to answer two questions at once. Do these medicines tend to improve lipids? Yes, the trial data point that way. And were those trials done in perimenopausal women, tracking cholesterol as the goal? No, they were not. I would rather you hold both of those than walk away with either false comfort or false worry. If you want a general, no-pressure starting point, our eligibility quiz is education, not a plan for your specific labs.

Why does cholesterol change during perimenopause?

Because the hormonal shift of these years reaches the lipid panel directly, not just the scale.

During the menopause transition, a decline in circulating estradiol and progesterone reaches well beyond reproductive health and significantly influences how the body handles energy. One of the clearest fingerprints of that shift shows up in cholesterol. Only total cholesterol, low-density lipoprotein cholesterol, and apolipoprotein B demonstrated substantial increases within the 1-year interval before and after the final menstrual period, consistent with menopause-induced changes.

That timing is the tell. These were not slow, decade-long drifts explained by getting older. They clustered right around the final period, which points to the menopause transition itself rather than chronological aging. And it matters for the heart. Women experience a unique increase in lipids at the time of the final menstrual period, and monitoring lipids in perimenopausal women should enhance primary prevention of coronary heart disease.

This does not sit in isolation. The menopause transition is a time of accelerating cardiovascular disease risk, and body fat is also relocating during these years. This pattern of fat redistribution is associated with a greater prevalence of cardiovascular disease risk factors and a higher incidence of cardiovascular disease events. We cover the fat side of that in perimenopause belly fat.

How does a GLP-1 affect cholesterol?

The clearest signal comes from the large obesity trials, where lipids were tracked as one of several cardiometabolic measures.

In STEP 1 to 3 and STEP 5, semaglutide led to greater reductions from baseline versus placebo in body weight, waist circumference, body mass index, systolic blood pressure, and diastolic blood pressure, as well as positive changes in glycated hemoglobin, C-reactive protein, and lipid levels. Pulling the program together, the summary is consistent. Overall, across the STEP trials, treatment with semaglutide 2.4 mg versus placebo improved cardiometabolic risk factors associated with obesity.

There is real weight change underneath those lipid numbers. In the STEP 1 trial, once-weekly semaglutide at 2.4 mg reduced body weight by 14.9% from baseline over 68 weeks, compared with 2.4% in the placebo group. The STEP 1 trial enrolled 1961 adults with obesity, or overweight with at least one weight-related condition, who did not have diabetes. So the lipid improvement is real, but notice who was studied. These were general adults with obesity, not women defined by perimenopause, and cholesterol was a secondary readout rather than the target.

It is worth adding that this class has shown a hard cardiovascular result too. In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. That was an events trial in people who already had heart disease, not a cholesterol study, so I keep it in its lane.

Is the benefit from the medicine or from weight loss?

Mostly from the weight loss, and that distinction changes how you should read the numbers.

The magnitude of weight loss achieved with these therapies can determine the level of improvement in various comorbidities. In other words, the lipid movement in these trials travels with the weight change rather than appearing as a separate, direct cholesterol effect. These are not lipid drugs in the way a statin is a lipid drug. They are weight medicines whose lipid benefit largely follows the pounds lost.

That is not a knock on them. It is just the honest mechanism, and it explains why the size of the cholesterol change tends to track the size of the weight change. If perimenopause is blunting your weight response, the terrain matters, which is why we wrote why perimenopause can slow your progress.

What should you watch during perimenopause?

This is the part where general education stops and individual care begins, so I will stay on the right side of that line.

The reasonable, non-prescriptive takeaway is the one the lipid research itself lands on. Monitoring lipids in perimenopausal women should enhance primary prevention of coronary heart disease. That means midlife is a sensible time to actually know your numbers, including LDL and, where available, apolipoprotein B, and to review them with a clinician who can see your full history. Whether any medicine belongs in that plan depends on far more than a cholesterol value, and it is not a decision an article can make for you. If the heart question is what is really on your mind, whether these medicines protect the heart after menopause is the companion to this one.

Frequently asked questions

Does a GLP-1 lower LDL cholesterol?

The trials point in a favorable direction rather than measuring LDL as a headline. In STEP 1 to 3 and STEP 5, semaglutide led to greater reductions from baseline versus placebo in body weight, waist circumference, body mass index, systolic blood pressure, and diastolic blood pressure, as well as positive changes in glycated hemoglobin, C-reactive protein, and lipid levels. Overall, across the STEP trials, treatment with semaglutide 2.4 mg versus placebo improved cardiometabolic risk factors associated with obesity. These are weight medicines whose lipid benefit largely follows the weight lost, not dedicated cholesterol drugs.

Why does cholesterol rise during perimenopause?

Because the change is tied to the menopause transition itself. Only total cholesterol, low-density lipoprotein cholesterol, and apolipoprotein B demonstrated substantial increases within the 1-year interval before and after the final menstrual period, consistent with menopause-induced changes. Women experience a unique increase in lipids at the time of the final menstrual period, and monitoring lipids in perimenopausal women should enhance primary prevention of coronary heart disease.

Is the cholesterol benefit proven in perimenopausal women?

Not directly. The lipid improvements come from obesity trials in general adults. The STEP 1 trial enrolled 1961 adults with obesity, or overweight with at least one weight-related condition, who did not have diabetes, and those studies did not select or analyze participants by menopausal status. Applying the finding to a perimenopausal woman is a fair extrapolation, not a measured result.

Should I start a GLP-1 to fix my cholesterol?

That is not a question an article should answer for you. The lipid benefit in the trials rides largely on weight loss, and whether a medicine fits your situation depends on your full history, your other risk factors, and a conversation with a licensed clinician. Knowing your numbers first is the sensible starting point.

References

1. J Am Coll Cardiol (2009). Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? PubMed PMID 20082925. https://pubmed.ncbi.nlm.nih.gov/20082925/ (Accessed 2026-07-25).
2. Circulation (2020). Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. PubMed PMID 33251828. https://pubmed.ncbi.nlm.nih.gov/33251828/ (Accessed 2026-07-25).
3. Estrogen and Metabolism: Navigating Hormonal Transitions from Perimenopause to Postmenopause (2025). PMC / National Library of Medicine. https://pmc.ncbi.nlm.nih.gov/articles/PMC12431702/ (Accessed 2026-07-25).
4. American journal of preventive cardiology (2026). Perimenopause as an obesogenic sensitive period: Contributions to elevated cardiovascular risk. PubMed PMID 41567597. https://pubmed.ncbi.nlm.nih.gov/41567597/ (Accessed 2026-07-25).
5. Postgrad Med (2022). Cardiometabolic risk factors efficacy of semaglutide in the STEP program. PubMed PMID 36691308. https://pubmed.ncbi.nlm.nih.gov/36691308/ (Accessed 2026-07-25).
6. The New England journal of medicine (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. PubMed PMID 33567185. https://pubmed.ncbi.nlm.nih.gov/33567185/ (Accessed 2026-07-25).
7. The New England journal of medicine (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. PubMed PMID 37952131. https://pubmed.ncbi.nlm.nih.gov/37952131/ (Accessed 2026-07-25).

---

*This article is general education and is not medical advice. It cannot tell you what is right for your body. Talk with a licensed clinician about your own situation.*

*Written and clinically reviewed by Dr. Linda Moleon, MD. Last reviewed 2026-07-25.*